A meta-analysis published in the Journal of the American Medical Association shows that off-label use of
atypical antipsychotics varies in benefit and risk. Researchers said Risperdal, Abilify and Zyprexa have a small but significant benefit for dementia patients. However, they found no evidence that atypical antipsychotics help those with an eating disorder or substance abuse. Furthermore, the drugs are associated with several risks, including stroke in the elderly and restless legs syndrome in younger patients.